Dulaglutide Reduces Binge Eating in Pilot Study in Diabetes Dulaglutide Reduces Binge Eating in Pilot Study in Diabetes

The GLP-1 agonist dulaglutide reduces binging in patients with type 2 diabetes and the eating disorder, as well as drops weight, fat mass, and A1c compared with gliclazide in a pilot study.Medscape Medical News
Source: Medscape Psychiatry Headlines - Category: Psychiatry Tags: Diabetes & Endocrinology News Source Type: news

Related Links:

ConclusionsEating psychopathology is frequently observed in patients with T2DM. Among individuals with T2DM, co-morbid ED is associated with a poorer glycemic control in the presence of a higher BMI. The presence of an eating disordered behavior in patients with T2DM seems to have clinical relevance in the usual care of patients with diabetes. Therefore, we recommend eating psychopathology should be routinely assessed in T2DM patients.
Source: Journal of Eating Disorders - Category: Eating Disorders & Weight Management Source Type: research
AbstractPurpose of ReviewTo present current data on the coexistence of attention deficit hyperactivity disorder (ADHD) and the metabolic syndrome and type 2 diabetes mellitus in adults and children and to discuss possible mechanisms.Recent FindingsEmerging data suggest that risk factors for obesity and insulin resistance such as diabetes during pregnancy and intrauterine growth failure may also have a role in the development of ADHD. Furthermore, ADHD and obesity share lifestyle factors, such as abnormal eating patterns, binge eating, and a sedentary lifestyle. ADHD is a risk factor for components of the metabolic syndrome...
Source: Current Diabetes Reports - Category: Endocrinology Source Type: research
ConclusionDysfunctional eating is present across the whole spectrum of T2DM and significantly impacts on adherence to dietary restriction and food choices.
Source: Nutrition, Metabolism and Cardiovascular Diseases - Category: Nutrition Source Type: research
We examined the effects of the independent and combined effects of Zataria Multiflora supplementation and circuit resistance training (CRT) on selected adipokines among postmenopausal women. Forty-eight postmenopausal women were divided into four groups: Exercise (EG, n = 12), Zataria Multiflora (ZMG, n = 12), exercise and Zataria Multiflora (ZMEG, n = 12), and control (CG, n = 12). Participants in experimental groups either performed CRT (3 sessions per week with intensity at 55% of one-repetition maximum) or supplemented with Zataria Multiflora (500 mg every day after breakfast with 100 ml of water), or their combination...
Source: Frontiers in Physiology - Category: Physiology Source Type: research
How can conventional dietary advice gotten it so wrong? Rather than eating plenty of “healthy whole grains,” people on the Wheat Belly lifestyle eat absolutely no grains and enjoy spectacular weight loss and reversal of hundreds of health conditions as a result. Unfortunately, many people view this as a “gluten-free” lifestyle which is incorrect. Here are 10 reasons why no bagels, pretzels, or sandwiches made from wheat flour should ever cross human lips. Gliadin-derived opioid peptides (from partial digestion to 4- and 5-amino acid long fragments) increase appetite substantially–as do related...
Source: Wheat Belly Blog - Category: Cardiology Authors: Tags: Wheat Belly Lifestyle Gliadin gluten Inflammation Weight Loss Source Type: blogs
Pancreatic β-cell failure in type 2 diabetes mellitus is a serious challenge that results in an inability of the pancreas to produce sufficient insulin to properly regulate blood glucose levels. Trace amine–associated receptor 1 (TAAR1) is a G protein–coupled receptor expressed by β-cells that has recently been proposed as a potential target for improving glycemic control and suppressing binge eating behaviors. We discovered that TAAR1 is coupled to Gαs-signaling pathways in insulin-secreting β-cells to cause protein kinase A (PKA)/exchange protein activated by cAMP (Epac)–dependent r...
Source: Journal of Biological Chemistry - Category: Chemistry Authors: Tags: Signal Transduction Source Type: research
ConclusionsBED and NES are common in adults with T2DM, and  BED is associated with higher BMI in patients with T2DM. However, only two studies reported important outcomes measures such as BMI and HbA1c in patients with T2DM. Hence, further well-designed studies are needed to assess the impact of BED and NES in patients with T2DM. Health Care Professionals should consider the diagnosis of BED and NES in patients with T2DM.
Source: Journal of Eating Disorders - Category: Eating Disorders & Weight Management Source Type: research
CONCLUSION: We found a complex gender-related association between MS, psychosocial risk factors and occupational determinants. The use of these information in surveillance workplace programs might prevent the onset of MS and decrease the chance of negative long-term outcomes. LEVEL OF EVIDENCE: Level V, observational study. PMID: 29987776 [PubMed - as supplied by publisher]
Source: Eating and weight disorders : EWD - Category: Eating Disorders & Weight Management Authors: Tags: Eat Weight Disord Source Type: research
Sleep-related eating disorder (SRED) is a parasomnia that links eating disorders to partial arousal during the transition between wakefulness and non-rapid eye movement (NREM) sleep. It is characterized by dysfunctional eating and drinking upon partial arousal from a stage of NREM sleep (also known as slow-wave sleep). As a form of sleepwalking, it entails partial or complete amnesia of the event. According to one study, the estimated prevalence of SRED was nearly 5% in the general population. The disorder is more common than generally recognized, and we can agree it requires more public awareness. This type of connection...
Source: Psych Central - Category: Psychiatry Authors: Tags: Diet & Nutrition Eating Disorders Neuroscience Sleep Stigma Stress Binge Eating Disorder Bingeing Disordered Eating nightmare disorder parasomnia restless leg syndrome Sleep apnea sleep disorder sleep hygiene sleep-related ea Source Type: news
Dear Colleagues: Welcome to the May–June 2018 issue of Innovations in Clinical Neuroscience (ICNS). We start the issue with a timely review article by Touma and Scarff titled, “Valbenazine and Deutetrabenazine for Tardive Dyskinesia (TD).” Here, the authors discuss the two drugs, which were recently approved by the United States Food and Drug Administration (FDA) for the treatment of TD. The authors describe the drugs’ unique mechanisms of action as well as the evidence supporting their efficacy, tolerability, dosing, drug interactions, and precautions. Next, in the article titled “Combinatio...
Source: Innovations in Clinical Neuroscience - Category: Neuroscience Authors: Tags: Current Issue Editor's Message: Issue Highlights Editorial Message Source Type: research
More News: Binge Eating Disorder | Diabetes | Diabetes Type 2 | Endocrinology | Psychiatry | Study